Resources

What an incredible night! Last Thursday, we welcomed a record 780 of you to the Roundhouse for the 2026 BIA Gala Dinner. It was a powerful reminder of the strength, resilience and sheer brilliance of our community.

In this blog, Saqib Lal, Head of Content at BIA, reflects on a stellar Gala Dinner. He describes it as a moment to pause and recognise the extraordinary people who make the UK life sciences sector a global powerhouse. This year, as a record 780 guests gathered at the iconic Roundhouse for an evening that demonstrated renewed ambition and positivity. 

As 2026 shapes up to an unpredictable year, our policy experts have provided more grounding for what the life sciences sector should expect over the next 12 months. This is the second and final part of our 2026 outlook series. 

Our UK biotech financing 2025 report is out today, including data and commentary on how the biotech investment landscape fared last year. 2025 was a brutal year for the sector, but an upswing in deal numbers going into 2026 and recent capital injections give good reason to be optimistic.

J.P. Morgan’s healthcare conference may be wrapped up, but it has set some tangible momentum and without doubt a more buoyant mood for global life sciences going into 2026.

In this blog, Linda Bedenik, Senior Policy and Public Affairs Manager at BIA, explores Biosolutions, defining what they are and their potential to solve global challenges beyond health.

OutSee, a genomics and drug discovery company pioneering a unique AI-based predictive genomics approach to target discovery, today announced the closure of its £2.5 million seed funding round.

This week JPM kicks off in San Francisco with BIA hosting a UK Reception. A significant week for BIA too with the long-awaited announcement of our new CEO.

Amici Procurement Solutions Rebrands as MyAmici. The rebrand reflects the organization’s strategic evolution from a procurement-focused provider to a comprehensive, end-to-end LabOps platform supporting biotech, medtech, and life-science organisations across every stage of growth.

Complement Therapeutics is one of the leading new gene therapy companies entering into clinical trials. Based on research from the University of Manchester, the company's lead candidate CTx001 is a novel adeno-associated virus (AAV)-based gene therapy targeting an advanced form of dry AMD that leads to irreversible vision loss, with limited therapeutic options. With strong funding and an experienced management team, Complement has made rapid progress and this Fast Track designation comes after IND clearance in December.

Relation and healthcare investment firm Deerfield Management, a current investor,  has launched a new research collaboration to advance therapeutic discovery projects for diseases of high unmet need.

Ikarovec Ltd and VectorBuilder entered into an exclusive worldwide option agreement for VectorBuilder’s novel AAV capsid technology to be used with Ikarovec’s gene therapy candidate IKAR-003.

Happy New Year to all our BIA members and collaborators. We hope that the break has provided an opportunity for a refresh, ready for a jam-packed 2026.

eXmoor Pharma and UCL have launched a new partnership to strengthen the pathway from academic research to GMP delivery, giving UCL innovators earlier access to CMC expertise, development capabilities and clinical manufacturing support to accelerate the translation of cell and gene therapies.

Proceeds will enable generation of full clinical data from ongoing Phase 1 study of TROCEPT-01 (ATTR-01), its lead programme in advanced solid tumours, and progression of TROCEPT-02 (ATTR-02) into the clinic.

Precision treatments tackling the hardest-to-treat cancers set to be produced from hundreds of tonnes of reprocessed uranium from nuclear reactors

Relation Therapeutics has announced a multi-program, strategic collaboration with Novartis to discover and advance novel targets for atopic diseases.

Four projects aimed at identifying the most promising repurposed drug candidates to treat motor neuron disease (MND) have been launched by the self-funded medical research organisation, LifeArc.

Cellular Origins, a TTP company that enables the manufacturing of cell therapies at scale, has completed a $40 million (EUR 34.3 million) over-subscribed Series A round.

BIA thought leadership takes centre stage with two key reports published: last week saw the release of 'From innovation to impact: unlocking patient access to innovative rare disease medicines', and today 'UK cell and gene therapy: driving efficiencies and innovation' celebrates real-world UK success.